Additionally, to test the effect of differing cellular Bcl-2 status, compounds 6a–k and 8a–b were evaluated for activity in the leukaemic cell lines KG1a (acute myelogenous leukaemia, Bcl-2 positive, [15]) and Jurkat (T-cell leukaemia, Bcl-2 negative, [16]). The gene discussed is BCL2; the disease is acute myeloid leukemia.